# IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

> **NCT04227769** · PHASE2 · TERMINATED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 18 (actual)

## Conditions studied

- Diabetes Mellitus Type 2 in Obese
- Inflammation
- Metabolic Disease
- Glucose Metabolism Disorders (Including Diabetes Mellitus)

## Interventions

- **DRUG:** Anakinra Prefilled Syringe

## Key facts

- **NCT ID:** NCT04227769
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-13
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Too low recruitment in group with patients with diabetes.
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227769, "IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04227769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*